Companies / AGN

ARGENICA THERAPEUTICS LIMITED

ASX:AGNPharmaceuticals, Biotechnology & Life Sciences
128.5M shares on issueASX (delayed) · snapshot 28 Oct 2026129.0M fully diluted+0.4% if every option and right converts$0.10price · delayed$13.5MMarket capAt the previous close. On a day the price moves, shares × today’s price will differ. Prices delayed.

Today’s holders own 99.6% of what they think they own, once every option and right converts.

Low
Dilution risk

Runway 2–4 quarters

MinimalVery high
Absolute levels — not a ranking against other companies.
Cash runway2.6 quarters of funding
Share-count growth (24m)0.3%
Raise cadence (24m)0 cash raises
Options & rights overhang0.4% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ARGENICA THERAPEUTICS LIMITED's ordinary share count was 128M as of July 2025, up 0.3% since September 2024, its latest share-count filing. The company has not raised capital through any placement, rights issue or share purchase plan in the past 24 months, and no proposed securities issues are pending. Options and rights on issue could convert into 500,000 new shares, equal to 0.4% of the current share count, none of which are in the money; the nearest expiry falls in May 2027. The company holds 2 to 4 quarters of funding at the recent spend rate, based on its most recent quarterly cash report for the June 2026 quarter.

AI-generated summary of this page's cited filings · updated 17 Oct 2026
Quick answers · 4

How much placement capacity does AGN have left?

None of the 15% placement capacity counted as used in the last 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.

How much cash does AGN have?

In its quarterly cash report for the quarter ended 30 June 2026, Argenica Therapeutics reported $6.4M of cash and estimated 4.0 quarters of funding available at its current rate of spending. That is the company's own estimate.

When do AGN's options expire?

Unexercised options and rights equal 0.4% of Argenica Therapeutics's shares on issue; the nearest expiry is May 2027.

How much has AGN's share count grown?

Argenica Therapeutics has 128.5M shares on issue as at 28 Oct 2026, up 0.3% over 24 months according to its Appendix 2A filings.

Get told when this changes
Get AGN alerts
Free for up to 2 companies. A daily email when AGN raises money, files a new share issue, drops below 2 quarters of cash or moves risk level.
0.4%
Options & rights overhang
0.0%
In the moneyAn option whose exercise price is below the last closing share price, so converting it pays. These are the options most likely to become new shares soon. supply
0
Raises · last 12 months
2.6 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 128.5M per ASX (delayed) (snapshot 28 Oct 2026).
128.1M128.2M128.3M128.4MDec 24Nov 25Oct 26128.5M

Cash runway

2.6 qtrs OURS
Two to four quarters of funding at the recent spend rate.
Funds operations to about June 2027 at the reported spend rate.
$4.2M cash after burn.
FILED 4.0 qtrs · $6.4M cash · quarter ended 30 June 2026
OURS our estimate, carried to todayOURSOur estimate for today. We take the cash in the company’s latest cash report, deduct spending since at its reported rate, and, for quarterly filers, add raises announced after it. It moves daily; announced money may not all be received yet.$6.4M cash at 30 Jun 2026 − $2.2M spent ($1.6M a quarter × 120 days) = $4.2M left → 2.6 qtrsFILED as the company reportedFILEDAs the company stated it in its latest cash report. Dated to the end of that period, it does not change until the next report.
Free account
14 cash reports on record — Cash runway history
Cash, net spend and cover trend from every Appendix 4C/5B and 4D/4E on record up to 30 June 2026.
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Issuance timeline

Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityOn issue, per this filingSource
13 Aug 20263H · cancellationAGN : ORDINARY FULLY PAID128.5MAppendix 3H
9 June 20263H · cancellationAGN : ORDINARY FULLY PAID128.5MAppendix 3H
20 Oct 20253G · unquotedAGN : ORDINARY FULLY PAID128.5MAppendix 3G
9 July 20252A · quoted issueAGN : ORDINARY FULLY PAID128.1MAppendix 2A
9 July 20253H · cancellationAGN : ORDINARY FULLY PAID128.1MAppendix 3H
Free account
22 filings on record — Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Securities on issue over time

Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.

Free account
Securities on issue, by class
How the share count and each option and rights class moved, month by month, with every number in a table.
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Capital raises

No equity raises in the last 24 months.
Free account
Full raise history
Issue price, shares issued, brokers and stated purpose for every raise on record.
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account
1 dated event on record — Forward supply calendar
Option expiries and proposed issues on one forward timeline, with the securities each could add.
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.

No Appendix 3B in the last 12 months reports an issue under the 15% placement capacity (as at 2026-10-28).
Free account
Placement capacity — LR 7.1 / 7.1A
The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.4%
Options & rights overhang · of current shares
0.0%
In-the-money supply · at current price
500k
Potential new shares
May 2027
Nearest expiry
What a price move would switch on
250k500k$0.10 now0.25× today ($0.03) — 0 of the priced supply in the money, 0.0% of shares on issue0.5× today ($0.05) — 0 of the priced supply in the money, 0.0% of shares on issue0.75× today ($0.08) — 0 of the priced supply in the money, 0.0% of shares on issue1× today ($0.10) — 0 of the priced supply in the money, 0.0% of shares on issue1.25× today ($0.13) — 0 of the priced supply in the money, 0.0% of shares on issue1.5× today ($0.16) — 0 of the priced supply in the money, 0.0% of shares on issue2× today ($0.21) — 0 of the priced supply in the money, 0.0% of shares on issue3× today ($0.32) — 0 of the priced supply in the money, 0.0% of shares on issue5× today ($0.53) — 0 of the priced supply in the money, 0.0% of shares on issue10× today ($1.05) — 500k of the priced supply in the money, 0.4% of shares on issue0.25×0.5×0.75×now1.25×1.5×2×3×5×10×

At $0.10 today, 0 securities are in the money (0.0% of shares on issue). No more priced supply until 10× today’s price, which takes it to 500k (0.4% of shares).

  • Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
CodeSecurityTypeExercise priceExpiryOn issueSource
AGNALOptionsPrice-triggered$0.9331 May 2027500kFiling

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.

1 class ceased in the last 12 months and is not counted above
The company’s own Appendix 2A restates each of these at zero. They are excluded from the overhang, the in-the-money supply and every figure on this page. Each count is the filing’s own count of securities in the class, not a share count — a 2A never states what one security converts into.
  • AGNAMPrice-triggered200k securities → 013 Aug 2026 Appendix 2A
Free account
1 option line on record — In-the-money value & price ladder
What each line is worth in the money today, the price ladder to the next tranche that converts, and the filing description behind every code.
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Director dealings

DateDirectorTypeSharesOptionsOtherValueSource
29 Sept 2026JEANNETTE JOUGHINBuy on-market143k——$20k3Y notice
3 June 2025LIZ DALLIMOREOther352k———3Y notice
Free account
2 notices on record — Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Free account: 2 full company unlocks every month, no card.
Unlock AGN freeSee plans

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Free account: 2 full company unlocks every month, no card.
Create free account

Latest announcements

20 Oct 2026$PNew Mechanism Findings Offer Insights Into Phase 2 Signal
20 Oct 2026Notice of Annual General Meeting/Proxy Form
29 Sept 2026Change of Director's Interest Notice
23 Sept 2026AGM Date & Closing Date for Director Nominations
15 Sept 2026Concussion Data Selected for Neurotrauma Congress
26 Aug 2026Appendix 4G & Corporate Governance Statement
26 Aug 2026$PAppendix 4E & Annual Report to 30 June 2026
13 Aug 2026Notification of cessation of securities - AGN
27 July 2026Investor Presentation - Techknow Conference
24 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
16 July 2026$PARG007 Shows Significant Neuroprotection in Concussion Study
11 June 2026Investor Webinar
11 June 2026Investor Presentation
11 June 2026$PARG007 (Xaranetide) Completes All Three FDA Requested Assays
10 June 2026$PWHO Confirms Xaranetide as INN for ARG-007
9 June 2026Notification of cessation of securities - AGN
26 May 2026Release of Securities from Voluntary Escrow
21 May 2026$PIND Application Advanced With Successful Completion of Assay
14 May 2026$PClinical Advisory Committee Established to Advance Phase 2b
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.